Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

David’s research will focus on immune dysregulation in colorectal and endometrial pre-cancers and cancers.

In healthy tissues, the body’s immune system is constantly looking for and destroying foreign pathogens and pre-cancerous/cancerous cells. For cancers to initiate and grow, they need to be able to evade this so-called immunosurveillance. A better understanding of how cancers evade immunosurveillance is needed to improve and develop new immune-based cancer treatments and prevention strategies, such as vaccination.

Dr David Church (Centre for Human Genetics, Nuffield Department of Medicine) has been awarded a prestigious Senior Cancer Research Fellowship by Cancer Research UK to study how immunosurveillance is disrupted in colorectal and endometrial pre-cancers and cancers. His research will focus on the dysregulation of two key complexes, called MHCI and MHC-II, that normally display foreign or damaged proteins to be recognised by the immune system.

On receiving the award, David said, “I am delighted to receive this fellowship, which will provide a secure platform for our research for the next six years. I am grateful to my group, many collaborators and patient representatives whose support was crucial.”

“This funding will allow us to take great strides in improving our understanding of how cancers evade the immune system and will be essential for developing better cancer treatments and informing new cancer preventatives.”

Similar stories

New vaccines that aim to prevent cancer: Starting the conversation

Join us for a joint event from the Centre for Personalised Medicine (CPM) & Oxford Centre for Cancer Early Detection and Prevention (OxCODE) on Monday 2nd June 2025.